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ABSTRACT 
Objective: The purpose of the study was to analyze the effect of clinical pharmacist intervention on glycemic control based on fasting blood glucose 
and glycosylated blood glucose level.  
Methods: A randomized prospective interventional study was conducted in the outpatient department of a tertiary care hospital. Patients suffering 
from diabetes for a least 2 y were selected for the study based on the inclusion and exclusion criteria. The control group was not given any special 
pharmacist care, while the interventional group had a face-to-face interview, counseling, and telephonic follow-up during the study period. Based on 
the baseline values and endpoint parametric values, the result of the study was analyzed.  
Results: The study was analyzed based on the difference in the glycemic index, using HbA1c and FBS values. The basal values of HbA1c were similar 
for both groups (8.5%), but a marked reduction to 7.2% was observed in the interventional group. FBS values reduced from 208 mg/dl to 186 
mg/dl in the intervention group, while in the usual care group, the reduction was from 211 mg/dl to 198 mg/dl.  
Conclusion: The inclusion of clinical pharmacists in the healthcare team can offer a remarkable improvement in patient's condition by providing 
more support in the therapy. 
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INTRODUCTION 
Diabetes Mellitus is one of the worldwide fastest emerging chronic 
metabolic disease which results in significantly raised morbidity, 
mortality and healthcare expenses. The international Diabetes 
foundation estimates diabetes in one in ten adults and about 47 % are 
under-diagnosed. Studies have shown that the risk factor for stroke 
and cardiovascular disease in diabetes patients is 2 to 3 times in 
contrast to patients having no hyperglycemia [1]. Moreover, the 
associated complications such as blindness, renal disease, and 
amputations increase health care costs dramatically high [2]. The cost 
of health care plans was calculated to be 2 to 3 times that of the patient 
of the same age without diabetes mellitus in the United States [3]. 
It was reported that there are different methods to prevent diabetes 
related morbidity [4]. One such method was by the utilization of the 
present management direction and positive changes in the 
monitoring of the pharmacotherapies, which included measuring 
blood sugar levels, and retinal screening. Patient education and 
motivation are the main two tools that can be applied to the clinical 
task for proper management of the condition. Most of the diabetes 
treatment purposes are mainly depending on self-management and 
life-altering changes of the patient. Therefore, the management of 
the complicated multisystem and patient-oriented problems in a 
healthcare system requires severe follow-ups and critical 
personalized patient counseling and proper medical education [5].  
The number of diabetic patient’s number is increasing yearly because 
of the increasing pervasiveness of both types of diabetes. To achieve 
strict control of diabetes, structured care is advised. In India, the 
diabetes clinical practice recommendations are inadequate in the 
primary care settings [6]. As a result, a number of modifications in the 
interventions designed to improve better metabolic control for 
diabetes patients have been developed [7]. Pharmacists are regarded 
as easy and fast accessible members of the healthcare team for the 
patients and are in a commendable status to participate in the 
professional care of the patients. Pharmacist-led, patient education 
and follow-up can improve the overall clinical outcome in patients. 
The management of T2DM needs continuous medical care by the 
healthcare team and self-care by patients. Despite all new medications 
and specific care in modern hospitals, the control of diabetes remains 
still in question. Pharmacists-led healthcare concept is found to help 
diabetic patients achieve treatment goals and improve outcomes. So, the 
introduction of pharmaceutical care is found to improve adherence of 
the patients to the prescribed regimen and individualized care, which 
results in better control of diabetes have been reported [8]. 
MATERIALS AND METHODS 
Patients in the age group 18 to 70 y of age, belonging to either 
gender, diagnosed with Type-2 diabetes mellitus for not more than 2 
y were selected. Patients with severe renal and hepatic dysfunctions 
were excluded. 
The study was conducted for a period of 12 mo, after gaining 
approval of the institutional Ethic committee (Approval no: 
JMCP/IEC-01A/PD-2018). During the period, patients who have 
diabetes for a maximum up to the past two years were selected. 
They were selected based on exclusion inclusion criteria and they 
were monitored. Patients who expressed willingness to participate 
in the study and otherwise satisfied the eligibility requirements 
were selected and the study details were well explained to all the 
participating patients and the duly signed informed consent was 
obtained. The selected patients were grouped randomly into 
interventional and usual care groups. The different intervention 
steps and the protocol of the study were explained to the patients 
included in the interventional group, whereas the normal care group 
was directed to follow their normal treatment protocol. Intervention 
procedures were applied to the selected interventional group, while 
the usual care group was not given any special attention or care in 
addition to normal care and information given by the healthcare 
team and pharmacist in the outpatient pharmacy department 
regarding the medications and therapeutic regimen. 
The multifaceted interventions for the patients in the interventional 
group were comprised of two sessions, a face-to-face care by an 
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interview and counseling followed by a telephonic follow up 
program. The interventional group was given regular six face-to-face 
informative sections spread over a period of 12 mo during their 
regular visit to the outpatient department for review. During this 
session the clinical pharmacist performed a 30 min face to face 
interaction and direct patient counseling. 
The most important responsibilities of the pharmacist are the 
optimization of the therapy and to improve medication adherence. A 
systemic review has shown that the intervention of a pharmacist 
through face-to-face interactions, group activities and telephonic 
follow-up can improve adherence in medications for diabetes patients. 
The responsibility of clinical pharmacy and clinical pharmacist-led 
patient care is a novel concept in pharmaceutical care. 
All the data collected were analyzed using SAS software. The 
demographic data and the baseline characteristics were summarized 
descriptively. Continuous variables were analyzed using unpaired t 
test and categorical data was analyzed by using the chi-square test at 
the baseline as well as by the end of the study at 5% significance. All 
differences were tested at p=5. 
RESULTS  
The fasting blood glucose levels were 208 mg/dl for the intervention 
group and 211 mg/dl and the usual care group at the baseline. The 
values were 198 mg/dl for the usual care and 186 mg/dl for the 
interventional group by the end of the study. In both groups the 
reduction was statistically significant. But the total reduction with 
the intervention group showed a statistical difference compared 
with the usual care group in group analysis (table 1, fig. 1). 
At the baseline assessment, the HbA1c values (8.5% and 8.7%) were 
similar for both interventional and usual care group. But, at the end of 
the study HbA1c values reduced to 7.2 % and 8.5%, respectively. The 
difference of the HbA1c percentage of the usual care group was not 
significant, but for the patients in the interventional group it was found 
significant. On compared with the usual care group, the interventional 
group patients achieved a greater reduction in the A1c values, which 
was clinically and statistically significant. It was found that in the 
intervention group the percentage of patients almost reached the 
American diabetes association goal (HbA1c ≤ 7%)  was significantly 
higher compared to the usual care group. 
  
Table 1: Outcomes in key biomedical values at baseline and end of study within and between groups 
Outcome 
measures 

































11.144 0.001 -15.912 








0.136 0.136 -1.061 
HbA1c= Glycosylated haemoglobin 
 
 
Fig. 1: Summary of fasting blood sugar 
 
 
Fig. 2: Summary of glycosylated hemoglobin (HbA1c) 
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DISCUSSION 
Out of the 220 selected candidates, the study was completed by 106 
patients in the interventional category and 104 patients in the usual 
care category. Among the four candidates from the intervention 
group discontinued, two were discontinued due to a change in their 
working area to other places in the government sector and two were 
changed to hospital for specialized treatment for their comorbidities. 
Among the six candidates in the usual care group, one changed 
hospital two candidates left the state to join their family and 3 went 
abroad with new job assignments. 
In both the interventional group (61.3%) and the usual care group 
(57.7%) majority were females. The age group of the patients varied 
from 41 to 70. Most of them belonged to the age group 56 to 60 
indicated the complications of the chronic diseases and associated 
complications starts after 50 y and before 60 y. 
The most common existing chronic disease is diabetes globally [9]. It 
was measured by changes in the HbA1c and FBS. In our study, these 
were evaluated and found that significant reductions were brought 
by the intervention and monitoring of the glucose level at home. The 
diabetic outpatients were nowadays giving more attention to non-
pharmacological lifestyle modifications for the management of blood 
glucose level. 
The final goal of the therapy was to achieve the HbA1c level less than 
or equal to 7%. It was achieved in the interventional group in 23.5% 
of the patients in the interventional group compared to 14.5% in the 
normally treated care group. Apart from the interactive involvement 
of the clinical pharmacist, there was diabetic education in the 
pharmacy for the diabetic patients, which also influenced patients 
belonging to both groups. Many studies conducted in diabetes 
patients showed improved glycemic control reported [10]. 
A significant reduction in HbA1c was observed in a study conducted 
among diabetes patients by the intervention pharmacist [11]. 
Another study reported that randomized controlled trials produced 
significant HbA1c levels within six months of duration due to the 
intervention of pharmacists [12]. 
Studies showed a significant statistical correlation between baseline 
glycemic values and final changes in HbA1c values. Most of the 
studies on diabetes showed a positive impact of pharmacist 
intervention. However, non-improvement adherence was also 
reported even after pharmacist intervention. Improvement in goal, 
was reported in pharmacist-managed diabetes patients [13]. 
A study conducted in Indonesia resulted in a decrease in mean HbAlc 
at all follow-ups and the number of patients with optimal HbAlc values 
increased after each follow-up [14]. Moreover, the lipid level improved 
at every measurement by about 50%. Patients with higher baseline 
HbA1c values pharmacist controlled diabetes, high baseline expenses 
were shown to have revamped or reduce the costs respectively. 
Pharmacist-controlled diabetes care decreased medication costs 
which is a significant factor for Pharmacoeconomics [15]. 
The need for clinical pharmacy services focused on diabetes, 
specifically in ambulatory care centre has been increased due to the 
increased mortality and morbidity due to diabetes. A retrospective 
study in which they evaluated outcomes for the management of 
diabetes referred to a clinical pharmacist with a control group who 
are not seen by a clinical pharmacist. It was observed that the 
diabetic patients who were managed by the clinical pharmacist had 
a higher decrease in HbAlc compared with the control group and 
also a reduction in the emergency department visits [16]. 
A study it was found that the basic outcome assessments in the 
changes in HbA1c, blood sugar were significantly decreased because 
of pharmacist participation in direct care. It was reported that the 
HbA1c was changed from the baseline by 2.2%, fasting blood sugar 
minimized by 65 mg/dl and the random blood sugar reduced by 
about 80 mg/dl.  
These results are similar to reviews performed by Yaghoubi et al., 
who have demonstrated a clinically significant decrease in HbA1c 
levels leading to improvement in type 2 diabetes condition [17]. It 
was also demonstrated a beneficial effect of pharmacist-led 
interventions when compared with normal care patients. 
Interventions with the active participation of pharmacist-centered 
diabetes awareness were comparable influence to pharmacist-led 
teaching and pharmacy care for blood sugar control measured as 
HbA1c and FBS along with several secondary clinical outcomes of 
the clinical responses. Health professionals are also supposed to 
provide a piece of proper knowledge to the patients regarding the 
role of pharmacotherapy and diet in diabetes control and its effect 
on these outcomes [18]. 
Our study demonstrated a 0.95% to 1.19% mean reduction in HbA1c 
compared with usual care within the first six months. Other studies 
which were conducted as pharmacist-based programs in other 
multidisciplinary health care settings were also shown a similar 
decrease in HbA1c from baseline with proactive pharmacist 
management [19]. However, some of these studies had fewer 
patients and shorter follow-up time periods. In a study, it was 
reported that diabetes patients managed by a pharmacist in a 
diabetes service center started with a mean HbA1c of 9 % and has 
decreased to 7.5% after seven months of follow-up, which was 
statistically significant over the control group. 
All these studies justified our finding of decreased blood sugar levels 
manifested by the reduction in the fasting blood sugar and HbA1c by 
interventions of the clinical pharmacist with patient counseling, 
diabetic education and personal follow up ultimately resulting in 
improved glycemic control. 
CONCLUSION 
The clinical pharmacist intervention resulted in a significant 
improvement in HbA1c and fasting blood glucose. During the study, 
the clinical pharmacist was involved in patient counselling and 
patient education to optimize pharmacotherapy. It was achieved 
through personal face-to-face interactions, supply of literatures and 
telephonic follow up. This has created an awareness of the patient 
not only in the appropriate use of medication but also the lifestyle 
modifications. The study also made an impact on the usual care 
group with their personal contacts with the intervention group 
members. Therefore, improved clinical outcomes were also 
observed in the usual care group. 
GLYCEMIC CONTROL 
In this study, the HbA1c value did not change much in the usual care 
group, whereas it was significantly reduced in the interventional 
category of patients. 
The Fasting Blood Sugar (FBS) level decreased in both usual care 
groups due to the improved diabetes care in the outpatient 
departments. But more pharmaceutical care do show a significant 
improvement in the other. 
The preeminent finding related to the blood glucose monitoring was 
that 37 percentage of the interventional group achieved the 
American Diabetes Association (ADA) target in the 12 mo of follow-
up. It is further proved that pharmaceutical care can result in a 
significant effect in blood glucose management in multiple clinical 
morbid conditions. 
LIMITATION 
One of the most important limitations was that in the retrospective 
observational study the patient data was collected from a single 
hospital, comparatively small patient size and a short follow-up study 
period. Interventions were carried out by a single clinical pharmacist. 
The study participants were treated by the same physician and by 
the same clinical pharmacist, so some of the positive clinical 
outcomes may be extrapolated to the normal group resulting 
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